These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6803339)

  • 1. [Study of a therapeutic concentrate of factor VIII/vWf prepared in a closed system].
    Mazurier C; Maillard J; Parquet-Gernez A; Goudemand M
    Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):25-43. PubMed ID: 6803339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
    Lethagen S; Berntorp E; Nilsson IM
    Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
    Meyer D; Obert B; Pietu G; Lavergne JM; Zimmerman TS
    J Lab Clin Med; 1980 Apr; 95(4):590-602. PubMed ID: 6965697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates.
    Lawrie AS; Harrison P; Armstrong AL; Wilbourn BR; Dalton RG; Savidge GF
    Br J Haematol; 1989 Sep; 73(1):100-4. PubMed ID: 2508742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U; Drewke E
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of von Willebrand factor in factor VIII concentrates.
    Fricke WA; Yu MY
    Am J Hematol; 1989 May; 31(1):41-5. PubMed ID: 2495715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
    Hillarp A; Friedman KD; Adcock-Funk D; Tiefenbacher S; Nichols WL; Chen D; Stadler M; Schwartz BA
    Haemophilia; 2015 Nov; 21(6):837-45. PubMed ID: 26172561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
    Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
    Brinkhous KM; Sandberg H; Garris JB; Mattsson C; Palm M; Griggs T; Read MS
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced yield of antihemophilic factor and von Willebrand factor by cryoprecipitation with polyethylene glycol.
    Johnson AJ; Macdonald VE; Brind J
    Vox Sang; 1979; 36(2):72-6. PubMed ID: 313629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.